APP and Alzheimer disease: Amyloid-beta precursor protein (APP) targeted by the monoclonal antibody aducanumab in the treatment of Alzheimer’s disease (AD) was ranked 506 (top 2.7%) prior to and 152 (top 0.8%) after diffusion on the STRING network (r = 0.6; Figure 6A) based on the eQTL-GWAS method.